A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Inclusion Criteria: * Treatment-naive CD30-positive mature T-cell and NK-cell neoplasms, including systemic anaplastic large cell lymphoma * Measurable disease of at least 1.5 cm * ECOG performance status less than or equal to 2 Exclusion Criteria: * Known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy * Current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, Sezary syndrome or other primary cutaneous lymphomas; extranodal NK/T-cell lymphoma, nasal type * History of another primary malignancy that has not been in remission for at least 3 years * Left ventricular ejection fraction \<45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months * Viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin * Known human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus positive status